Elevation of plasma soluble human leukocyte antigen-G in patients with chronic hepatitis C virus infection

Human Immunology

Volumn 72, Issue 5, 2011, Pages 406-411

  Weng, Peng Jian ^a   Fu, Yan Min ^a   Ding, Shi Xiong ^a   Xu, Dan Ping ^b   Lin, Aifen ^b   Yan, Wei Hua ^b  

^a Infectious Diseases Hospital of Ningbo   (China)

^b TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

Genotype; Hepatitis C virus; SHLA G

Indexed keywords

GAMMA INTERFERON; HLA G ANTIGEN; INTERLEUKIN 10; SOLUBLE HUMAN LEUKOCYTE ANTIGEN G1; SOLUBLE HUMAN LEUKOCYTE ANTIGEN G5; UNCLASSIFIED DRUG; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS LOAD; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; DNA, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNE EVASION; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 79954577776     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2011.02.008     Document Type: Article

References (47)

1. Pawlotsky J.M. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 2004, 12:96-102.
2. Hahn Y.S. Subversion of immune responses by hepatitis C virus: Immunomodulatory strategies beyond evasion?. Curr Opin Immunol 2003, 15:443-449.
3. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:s21-s29.
4. El-Serag H.B., Hampel H., Yeh C., Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002, 36:1439-1445.
5. Eckels D.D., Wang H., Bian T.H., Tabatabai N., Gill J.C. Immunobiology of hepatitis C virus (HCV) infection: The role of CD4 T cells in HCV infection. Immunol Rev 2000, 174:90-97.
6. Erickson A.L., Kimura Y., Igarashi S., Eichelberger J., Houghton M., Sidney J., et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001, 15:883-895.
7. Koziel M.J., Dudley D., Afdhal N., Choo Q.L., Houghton M., Ralston R., et al. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 1993, 67:7522-7532.
8. Ellis S.A., Palmer M.S., McMichael A.J. Human trophoblast and the choriocarcinoma cell line BeWo express a truncated HLA class I molecule. J Immunol 1990, 144:731-735.
9. Carosella E.D., Moreau P., Lemaoult J., Rouas-Freiss N. HLA G: From biology to clinical benefits. Trends Immunol 2008, 29:125-132.
10. Rizzo R., Melchiorri L., Stignani M., Baricordi O.R. HLA G expression is a fundamental prerequisite to pregnancy. Hum Immunol 2007, 68:244-250.
11. Paul P., Cabestre F.A., Ibrahim E.C., Lefebvre S., Khalil-Daher I., Vazeux G., et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 2000, 61:1138-1149.
12. Park G.M., Lee S., Park B., Kim E., Shin J., Cho K., et al. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun 2004, 313:606-611.
13. Rebmann V., Busemann A., Lindemann M., Grosse-Wilde H. Detection of HLA-G5 secreting cells. Hum Immunol 2003, 64:1017-1024.
14. Pistoia V., Morandi F., Wang X., Ferrone S. Soluble HLA-G: Are they clinically relevant?. Semin Cancer Biol 2007, 17:469-479.
15. Couper K.N., Blount D.G., Riley E.M. IL-10: The master regulator of immunity to infection. J Immunol 2008, 180:5771-5777.
16. Moreau P., Adrian-Cabestre F., Menier C., et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 1999, 11:803-811.
17. Yang Y., Chu W., Geraghty D.E., Hunt J.S. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. J Immunol 1996, 156:4224-4231.
18. Rizzo R., Mapp C.E., Melchiorri L., et al. Defective production of soluble HLA-G molecules by peripheral blood monocytes in patients with asthma. J Allergy Clin Immunol 2005, 115:508-513.
19. Ugurel S., Rebmann V., Ferrone S., Tilgen W., Grosse-Wilde H., Reinhold U., et al. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 2001, 92:369-376.
20. Lafon M. Immune evasion, a critical strategy for rabies virus. Dev Biol 2008, 131:413-419.
21. LeBouder F., Khoufache K., Menier C., Mandouri Y., Keffous M., Lejal N., et al. Immunosuppressive HLA-G molecule is upregulated in alveolar epithelial cells after influenza A virus infection. Hum Immunol 2009, 70:1016-1019.
22. Yan W.H., Lin A., Chen B.G., Chen S.Y. Induction of both membrane-bound and soluble HLA-G expression in active human cytomegalovirus infection. J Infect Dis 2009, 200:820-826.
23. Lajoie J., Fontaine J., Tremblay C., Routy J.P., Poudrier J., Roger M., et al. Persistence of high levels of blood soluble human leukocyte antigen-G is associated with rapid progression of HIV infection. AIDS 2009, 23:1437-1440.
24. Souto F.J., Crispim J.C., Ferreira S.C., da Silva A.S., Bassi C.L., Soares C.P., et al. Liver HLA-G expression is associated with multiple clinical and histopathological forms of chronic hepatitis B virus infection. J Viral Hepatitis 2011, 18:102-105.
25. Lafon M., Prehaud C., Megret F., Lafage M., Mouillot G., Roa M., et al. Modulation of HLA-G expression in human neural cells after neurotropic viral infections. J Virol 2005, 79:15226-15237.
26. Cordero E.A., Veit T.D., da Silva M.A., Jacques S.M., Silla L.M., Chies J.A., et al. HLA-G polymorphism influences the susceptibility to HCV infection in sickle cell disease patients. Tissue Antigens 2009, 74:308-313.
27. National program for prevention and treatment of viral hepatitis. Chin J Hepatol 2000, 8:324-329. Chinese Society of Infectious Diseases and Parasitology and Chinese Society of Hepatology of Chinese Medical Association.
28. Okamoto H., Sugiyama Y., Okada S., Kurai K., Akahane Y., Sugai Y., et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 1992, 73:673-679.
29. Bode J.G., Brenndörfer E.D., Häussinger D. Subversion of innate host antiviral strategies by the hepatitis C virus. Arch Biochem Biophys 2007, 462:254-265.
30. Szabo G., Dolganiuc A. Hepatitis C and innate immunity: Recent advances. Clin Liver Dis 2008, 12:675-692.
31. +T cells and V alpha 24+ natural killer T cells in chronic hepatitis C viral infection. J Hepatol 2002, 37:101-108.
32. Corado J., Toro F., Rivera H., Bianco N.E., Deibis L., De Sanctis J.B., et al. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol 1997, 109:451-457.
33. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999, 10:439-449.
34. Chisari F.V. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997, 99:1472-1477.
35. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000, 6:578-582.
36. LeMaoult J., Rouas-Freiss N., Carosella E.D. Immuno-tolerogenic functions of HLA-G: Relevance in transplantation and oncology. Autoimmun Rev 2005, 4:503-509.
37. Carosella E.D., HoWangYin K.Y., Favier B., LeMaoult J. HLA-G-dependent suppressor cells: Diverse by nature, function, and significance. Hum Immunol 2008, 69:700-707.
38. Onno M., Pangault C., Le Friec G., Guilloux V., André P., Fauchet R., et al. Modulation of HLA-G antigens expression by human cytomegalovirus: Specific induction in activated macrophages harboring human cytomegalovirus infection. J Immunol 2000, 164:6426-6434.
39. Chang C.C., Murphy S.P., Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: Potential mechanisms. Hum Immunol 2003, 64:1057-1063.
40. Larsen M.H., Hviid T.V. Human leukocyte antigen-G polymorphism in relation to expression, function, and disease. Hum Immunol 2009, 70:1026-1034.
41. Díaz-Valdés N., Manterola L., Belsúe V., Riezu-Boj J.I., Larrea E., Echeverria I., et al. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology 2011, 53:23-31.
42. Kanto T. Virus associated innate immunity in liver. Front Biosci 2008, 13:6183-6192.
43. Lin A., Chen H.X., Zhu C.C., Zhang X., Xu H.H., Zhang J.G., et al. Aberrant human leukocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J Cell Mol Med 2010, 14:2162-2171.
44. Cai M.Y., Xu Y.F., Qiu S.J., Ju M.J., Gao Q., Li Y.W., et al. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin Cancer Res 2009, 15:4686-4693.
45. Bartosch B., Thimme R., Blum H.E., Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol 2009, 51:810-820.
46. Rouas-Freiss N., Moreau P., Menier C., LeMaoult J., Carosella E.D. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 2007, 17:413-421.
47. Urosevic M., Dummer R. Human leukocyte antigen-G and cancer immunoediting. Cancer Res 2008, 68:627-630.